

REMARKS

Claims 58-61, 109 and 123 were pending in the present application. Applicants have canceled 58-61, 109 and 123 without prejudice and introduced new claims 124-143, which are directed to substantially pure Form F and pharmaceutical dosage forms comprising Form F.

Support for new claims 124-143 can be found, *inter alia*, on page 2, lines 14-24 and page 32, line 25 – page 33, line 26 of the original specification. Therefore, new claims 124-143 are fully supported by the original specification and do not raise any issue of new matter. Accordingly, entry of the present preliminary amendment is respectfully requested. Upon entry of the present preliminary amendment, claims 124-143 will be under examination.

CONCLUSION

Applicants respectfully request entry of the present preliminary amendment and favorable consideration of all pending claims.

It is believed that no fee is deemed necessary in connection with the filing of the present preliminary amendment. However, if any fees are required, the Commissioner is hereby authorized to charge any such fees to our Deposit Account No. 16-1445.

Date: 04/29/05

Respectfully submitted,

Lance Y. Liu

Lance Y. Liu

Attorney for Applicant(s)

Reg. No. 45,379

Customer No. 28523

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-1652